{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:02:47Z","timestamp":1780959767289,"version":"3.54.1"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Zentralbl Chir"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1055\/a-2507-2643","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:42:58Z","timestamp":1780958578000},"page":"316-327","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative molekulare Testung beim nicht kleinzelligen Lungenkarzinom"],"prefix":"10.1055","volume":"151","author":[{"given":"Uyen-Thao","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Maria","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","article-title":"Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)","volume":"152","author":"F Griesinger","year":"2021","journal-title":"Lung Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s44258-024-00033-3","article-title":"Challenges and prospects in utilizing technologies for gene fusion analysis in cancer diagnostics","volume":"2","author":"X Su","year":"2024","journal-title":"Med-X"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jtho.2019.07.005","article-title":"Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study","volume":"14","author":"E Conde","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"JP Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jmoldx.2021.07.027","article-title":"Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions","volume":"23","author":"HJ Park","year":"2021","journal-title":"J Mol Diagn"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102200","article-title":"Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study","volume":"9","author":"DW Kang","year":"2024","journal-title":"ESMO Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"V Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)","volume":"35","author":"MA Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer","volume":"130","author":"AC Tan","year":"2024","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.chest.2024.05.026","article-title":"The Proposed Ninth Edition TNM Classification of Lung Cancer","volume":"166","author":"FC Detterbeck","year":"2024","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"383","author":"YL Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"M Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"YL Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study","volume":"42","author":"CM Blakely","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"D Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"T Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"JV Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"H Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"PM Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer","volume":"43","author":"J He","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2025.43.16_suppl.8015","article-title":"Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01\u20132020-ML42316)","volume":"43(16 Suppl.)","author":"A Leonetti","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jtho.2025.09.122","article-title":"MA04.02 NAUTIKA1: Clinical Outcomes and Pathologic Regression with Neoadjuvant Alectinib in Resectable Stage IB\u2212IIIB ALK+ NSCLC","volume":"20","author":"JM Lee","year":"2025","journal-title":"J Thorac Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"C Liu","year":"2020","journal-title":"Cancer Lett"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"A Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.2217\/fon-2022-0656","article-title":"LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer","volume":"18","author":"M Tsuboi","year":"2022","journal-title":"Future Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial","volume":"39","author":"WZ Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.22.00428","article-title":"Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer","volume":"40","author":"D Yue","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study","volume":"161","author":"Y Zhang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1038\/s41467-023-40349-z","article-title":"Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study","volume":"14","author":"D Bian","year":"2023","journal-title":"Nat Commun"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","article-title":"The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC","volume":"29","author":"AEB Chang","year":"2024","journal-title":"Oncologist"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"WZ Zhong","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009677","article-title":"Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer","volume":"12","author":"N Zhou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"AJ Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34626","article-title":"Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis","volume":"10","author":"Z Peng","year":"2024","journal-title":"Heliyon"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"B Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001282","article-title":"Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer","volume":"8","author":"JE Reuss","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390290","article-title":"Immune Resistance Mechanisms and the Road to Personalized Immunotherapy","volume":"43","author":"M Piper","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"DB Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"DR Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Q Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Z Liu","year":"2025","journal-title":"Cell"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41598-024-83067-2","article-title":"DNA mismatch repair (MMR) genes expression in lung cancer and its correlation with different clinicopathologic parameters","volume":"15","author":"MS Farrag","year":"2025","journal-title":"Sci Rep"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103494","article-title":"Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure","volume":"9","author":"RJ Huang","year":"2024","journal-title":"ESMO Open"}],"container-title":["Zentralblatt f\u00fcr Chirurgie - Zeitschrift f\u00fcr Allgemeine, Viszeral-, Thorax- und Gef\u00e4\u00dfchirurgie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2507-2643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:43:12Z","timestamp":1780958592000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2507-2643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2507-2643","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-409X","1438-9592"],"issn-type":[{"value":"0044-409X","type":"print"},{"value":"1438-9592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}